HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael S. Mulligan Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farivar, A. S. Articles by Mulligan, M. S. Search for Related Content PubMed PubMed Citation Articles by Farivar, A. S. Articles by Mulligan, M. S. Related Collections Lung - transplantation

Ann Thorac Surg 2006;82:472-478
© 2006 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Interleukin-6 Regulation of Direct Lung Ischemia Reperfusion Injury

Division of Thoracic Surgery, University of Washington Medical Center, Seattle, Washington

Accepted for publication March 14, 2006.

^_* Address correspondence to Dr Mulligan, University of Washington Medical Center, 1959 NE Pacific St, Box 356310, Seattle, WA 98195. (Email: msmmd{at}u.washington.edu).

Presented at the Poster Session of the Forty-second Annual Meeting of The Society of Thoracic Surgeons, Chicago, IL, Jan 30–Feb 1, 2006.

BACKGROUND: Lung ischemia reperfusion injury continues to adversely affect patient and graft survival after transplantation. While the role of interleukin-6 has been studied in ischemia-reperfusion models of intestine, liver, and heart, its participation in lung reperfusion injury has not been characterized.

METHODS: We administered recombinant interleukin-6 to rat lungs through the intratracheal route before inducing left lung ischemia and reperfusion. Multiple in-vivo indicators of left lung injury were studied, as were transactivation patterns for nuclear factor kappa B and signal transduction and activators of transcription-3. Downstream effects on the elaboration of proinflammatory chemokines and cytokines were also studied.

RESULTS: Recombinant interleukin-6 reduced endothelial disruption and neutrophil sequestration in left lung and alveolar spaces, resulting in improved oxygenation after ischemia and 4 hours of reperfusion. This protection was associated with decreased nuclear factor kappa B and signal transduction and activators of transcription-3 nuclear translocation early in reperfusion, and diminished proinflammatory mediator secretion late in reperfusion.

CONCLUSIONS: Further studies focusing on the effects of recombinant interleukin-6 in large animal models are warranted, as this may be a novel strategy to improve outcomes after lung transplantation. Intratracheal administration may focus its efficacy on the lung while reducing effects on other organ systems during organ procurement.

This article has been cited by other articles:

				B. P. van Putte, P. M. Cobelens, N. van der Kaaij, B. Lachmann, A. Kavelaars, C. J. Heijnen, and J. Kesecioglu Exogenous surfactant attenuation of ischemia-reperfusion injury in the lung through alteration of inflammatory and apoptotic factors J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 824 - 828. [Abstract] [Full Text] [PDF]

				T. K. Varghese Jr Invited commentary Ann. Thorac. Surg., August 1, 2006; 82(2): 478 - 479. [Full Text] [PDF]